Cargando…

Dosage reduction of low weight heparin in patients with renal dysfunction: Effects on anti-Xa levels and clinical outcomes

BACKGROUND: To prevent bio-accumulation of low molecular weight heparins (LMWHs) in patients with decreased kidney function, dosage reduction and anti-Xa monitoring has been suggested. The aim of this study was to investigate the effect of pre-emptive dosage reduction of LMWH on anti-Xa levels. Furt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hornung, Paul, Khairoun, Meriem, Dekker, Friedo W., Kaasjager, Karin A. H., Huisman, Albert, Jakulj, Lily, Bos, Willem Jan W., Rosendaal, Frits R., Verhaar, Marianne C., Ocak, Gurbey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529211/ https://www.ncbi.nlm.nih.gov/pubmed/33001983 http://dx.doi.org/10.1371/journal.pone.0239222

Ejemplares similares

Migration background and COVID-19 related intensive care unit admission and mortality in the Netherlands: A cohort study
por: Ocak, Gurbey, et al.
Publicado: (2023)

The incidence, mortality and renal outcomes of acute kidney injury in patients with suspected infection at the emergency department
por: Khairoun, Meriem, et al.
Publicado: (2021)

Chronic kidney disease and atrial fibrillation: A dangerous combination
por: Ocak, Gurbey, et al.
Publicado: (2022)

Vitamin K antagonist use and renal function in pre-dialysis patients
por: Voskamp, Pauline WM, et al.
Publicado: (2018)

Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study
por: Koks, Marije S., et al.
Publicado: (2021)

Hematological Ratios Are Associated with Acute Kidney Injury and Mortality in Patients That Present with Suspected Infection at the Emergency Department
por: de Hond, Titus A. P., et al.
Publicado: (2022)

Von Willebrand factor, ADAMTS13 and mortality in dialysis patients
por: Ocak, Gurbey, et al.
Publicado: (2021)

Type of arteriovenous vascular access and association with patency and mortality
por: Ocak, Gürbey, et al.
Publicado: (2013)

Bleeding risk of haemodialysis and peritoneal dialysis patients
por: van Eck van der Sluijs, Anita, et al.
Publicado: (2020)

Course of Symptoms and Health-Related Quality of Life during Specialized Pre-Dialysis Care
por: de Goeij, Moniek C. M., et al.
Publicado: (2014)

Single Nucleotide Variants in the Protein C Pathway and Mortality in Dialysis Patients
por: Ocak, Gürbey, et al.
Publicado: (2014)

Candidate Gene Analysis of Mortality in Dialysis Patients
por: Rothuizen, Tonia C., et al.
Publicado: (2015)

Factor Xa Generation by Computational Modeling: An Additional Discriminator to Thrombin Generation Evaluation
por: Brummel-Ziedins, Kathleen E., et al.
Publicado: (2012)

Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
por: de Jong, Ype, et al.
Publicado: (2021)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Evaluation of anti-Xa levels in patients with venous thromboembolism within the first 48 h of anticoagulation with unfractionated heparin
por: Nguyen, Lily, et al.
Publicado: (2023)

Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy
por: Byun, Jung-Hyun, et al.
Publicado: (2016)

Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy
por: McLaughlin, Kevin, et al.
Publicado: (2019)

Ambiguous definitions for baseline serum creatinine affect acute kidney diagnosis at the emergency department
por: Niemantsverdriet, Michael, et al.
Publicado: (2021)

Elucidating the specificity of non-heparin-based conformational activators of antithrombin for factor Xa inhibition
por: Rashid, Qudsia, et al.
Publicado: (2014)

Overweight and obesity are not associated with worse clinical outcomes in COVID-19 patients treated with fixed-dose 6 mg dexamethasone
por: Wittermans, Esther, et al.
Publicado: (2022)

Prediction or causality? A scoping review of their conflation within current observational research
por: Ramspek, Chava L., et al.
Publicado: (2021)

Anti-Xa level monitoring of low-molecular-weight heparin during intermittent venovenous hemofiltration
por: Xu, Lengnan, et al.
Publicado: (2023)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Acute Rejection After Kidney Transplantation Associates With Circulating MicroRNAs and Vascular Injury
por: Bijkerk, Roel, et al.
Publicado: (2017)

Relationship between peak anti-Xa levels and calculated creatinine clearance in ICU patients receiving low molecular weight heparin
por: McDonald, E, et al.
Publicado: (2003)

Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study
por: Jochberger, Stefan, et al.
Publicado: (2005)

Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms
por: Whitman-Purves, Emily, et al.
Publicado: (2017)

Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
por: Lawlor, Matthew, et al.
Publicado: (2021)

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?
por: Nguyen, Tung Phi, et al.
Publicado: (2021)

Monitoring Low Molecular Weight Heparins at Therapeutic Levels: Dose-Responses of, and Correlations and Differences between aPTT, Anti-Factor Xa and Thrombin Generation Assays
por: Thomas, Owain, et al.
Publicado: (2015)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

An XA21-Associated Kinase (OsSERK2) Regulates Immunity Mediated by the XA21 and XA3 Immune Receptors
por: Chen, Xuewei, et al.
Publicado: (2014)

Xa tantlin lisantiago /
por: Ibarra, José Xochihua
Publicado: (1993)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
por: Rhoades, Ruben, et al.
Publicado: (2021)

Usefullness of Heparin Calibrated Anti-Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
por: Riahi, Nada, et al.
Publicado: (2023)

Decreasing incidence of dialysis in older patients in The Netherlands as compared with other European countries: an international perspective
por: van Oevelen, Mathijs, et al.
Publicado: (2023)

Dosage of heparin for patency of the totally implanted central venous catheter in cancer patients
por: de Oliveira, Francisca Jane Gomes, et al.
Publicado: (2020)

Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19
por: Martinelli, Ida, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u1p69gqecqh3q4deafv1rug5mr